Literature DB >> 6975681

Spontaneous and antibody-dependent cellular cytotoxicity by lymphocyte subpopulations in peripheral blood and spleen from adult untreated patients with Hodgkin's disease.

S Gupta, G Fernandes.   

Abstract

Subpopulations of lymphocytes in the peripheral blood and spleen from adult untreated patients with Hodgkin's disease were studied for spontaneous (SCMC) and antibody-dependent cellular cytotoxicities (ADCC). Peripheral blood from seven of 24 patients demonstrated abnormally low T cell-mediated SCMC when compared to age- and sex-matched healthy controls. Only two of these patients also demonstrated low T cell ADCC and non-T cell-mediated SCMC and ADCC. T cell ADCC in the peripheral blood of patients with involved spleen was significantly higher (P less than 0.05) when compared to those in whom spleen was not involved. When SCMC and ADCC were compared between peripheral blood and splenic lymphocytes with regard to involvement of spleen by Hodgkin's disease, non-T cell SCMC in the involved spleen was significantly lower (P less than 0.05) than their peripheral blood non-T cell SCMC. SCMC and ADCC tended to be higher in patients with stages III and IV of Hodgkin's disease when compared to those with stages I and II. However, the differences were not statistically significant. No direct relationship was observed between T and SCMC or ADCC and the proportion of T cells with IgG Fc receptors (T gamma). The significance of these observations is discussed.

Entities:  

Mesh:

Year:  1981        PMID: 6975681      PMCID: PMC1537263     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  50 in total

1.  Hodgkin's disease and immunity.

Authors:  W W SCHIER; A ROTH; G OSTROFF; M H SCHRIFT
Journal:  Am J Med       Date:  1956-01       Impact factor: 4.965

2.  Antibody-dependent cytotoxicity mediated by human Fc-receptor-bearing cells lacking markers for B- and T-lymphocytes.

Authors:  F Wisloff; S S Froland; T E Michaelsen
Journal:  Int Arch Allergy Appl Immunol       Date:  1974

3.  In vitro leukocyte interferon production in patients with Hodgkin's disease.

Authors:  A L Rassiga-Pidot; O R McIntyre
Journal:  Cancer Res       Date:  1974-11       Impact factor: 12.701

4.  Interferon, antibody, and other host factors in herpes zoster.

Authors:  D A Stevens; T C Merigan
Journal:  J Clin Invest       Date:  1972-05       Impact factor: 14.808

5.  Impaired lymphocyte function in untreated Hodgkin's disease.

Authors:  R Levy; H S Kaplan
Journal:  N Engl J Med       Date:  1974-01-24       Impact factor: 91.245

6.  Quantitation of T and B lymphocytes and cellular immune function in Hodgkin's disease.

Authors:  A M Bobrove; Z Fuks; S Strober; H S Kaplan
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

7.  Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells.

Authors:  R B Herberman; M E Nunn; H T Holden; D H Lavrin
Journal:  Int J Cancer       Date:  1975-08-15       Impact factor: 7.396

8.  Lymphocyte abnormalities in untreated patients with Hodgkin's disease.

Authors:  G Holm; H Mellstedt; M Björkholm; B Johansson; D Killander; R Sundblad; G Söderberg
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

9.  Hodgkin's disease. An immunodepleting and immunosuppressive disorder.

Authors:  J J Twomey; A H Laughter; S Farrow; C C Douglass
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

10.  Cytotoxic lymphocytes from normal donors. A functional marker of human non-T lymphocytes.

Authors:  H F Pross; M Jondal
Journal:  Clin Exp Immunol       Date:  1975-08       Impact factor: 4.330

View more
  9 in total

1.  Bone marrow and peripheral blood natural killer cell activity in lymphomas. Its response to IL-2.

Authors:  L H Caldera; M Leon-Ponte; G Acquatella; N E Bianco; I Blanca
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

2.  Abnormality of Leu 2+7+ cells in acquired immune deficiency syndrome (AIDS), AIDS-related complex, and asymptomatic homosexuals.

Authors:  S Gupta
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

3.  Clinical significance of natural killing activity in patients with advanced lymphoma.

Authors:  K Ono
Journal:  J Clin Immunol       Date:  1998-03       Impact factor: 8.317

4.  Interferon-alpha induction of lymphocytes containing parallel tubular structures.

Authors:  Y L Hoogeveen; J W Smit; N R Blom; M J van Luyn; R M Halie
Journal:  Blut       Date:  1988-02

5.  Frequently relapsing minimal change nephrotic syndrome with natural killer cell deficiency prior to the overt relapse of Hodgkin's disease.

Authors:  T Mori; A Yabuhara; J Nakayama; M Kitahara; K Washizawa; S Kasai; A Komiyama
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

6.  Surface markers and cytotoxic activity of blood natural killer cells studied at the single cell level in Hodgkin's disease.

Authors:  E Jezewska; M Björkholm; R Giscombe; G Holm; O Tullgren
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

7.  Natural killing activity in patients with spontaneous regression of malignant lymphoma.

Authors:  K Ono; M Kikuchi; N Funai; M Matsuzaki; Y Shimamoto
Journal:  J Clin Immunol       Date:  1996-11       Impact factor: 8.317

8.  Modulation of human natural killer cell activity by pharmacological mediators.

Authors:  T J Hall; S H Chen; J Brostoff; P M Lydyard
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

9.  Natural killer (NK) activity in the spleen of patients with Hodgkin's disease and controls.

Authors:  S Al Sam; D B Jones; S V Payne; D H Wright
Journal:  Br J Cancer       Date:  1982-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.